BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, Florio A, Loria P. Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. World J Gastroenterol 2014; 20(13): 3410-3417 [PMID: 24707124 DOI: 10.3748/wjg.v20.i13.3410] [Cited by in CrossRef: 107] [Cited by in F6Publishing: 97] [Article Influence: 17.8] [Reference Citation Analysis]
Number Citing Articles
1 Solis JG, Enciso López ES, Bautista Santos A, Anda Garay JC, Calixto Rodríguez JL, Moreno Alcántar R, Montiel López L. Effect of Direct Antiviral Agents on Atherosclerosis in Patients with Chronic Hepatitis C. Arch Med Res 2021:S0188-4409(21)00115-6. [PMID: 33972118 DOI: 10.1016/j.arcmed.2021.04.009] [Reference Citation Analysis]
2 Revuelto Artigas T, Zaragoza Velasco N, Gómez Arbones X, Vidal Ballester T, Piñol Felis C, Reñe Espinet JM, Betriu Bars A. Chronic hepatitis C infection: An independent risk factor for subclinical atheromatosis. Rev Clin Esp (Barc) 2019;219:293-302. [PMID: 30773286 DOI: 10.1016/j.rce.2018.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
3 Sliem HA, Salem AS, Hussien WM, El Sayed HRA. Arterial wall structural changes in noncirrhotic chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2019;31:1432-8. [PMID: 31569123 DOI: 10.1097/MEG.0000000000001429] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Adinolfi LE, Nevola R, Rinaldi L, Romano C, Giordano M. Chronic Hepatitis C Virus Infection and Depression. Clin Liver Dis 2017;21:517-34. [PMID: 28689590 DOI: 10.1016/j.cld.2017.03.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
5 Kanellopoulou T, Alexopoulou A, Kontopidou FN, Konstantinides P, Papatheodoridis GV. The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking. Ann Gastroenterol 2016;29:201-7. [PMID: 27065733 DOI: 10.20524/aog.2016.0013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Olubamwo OO, Onyeka IN, Miettola J, Kauhanen J, Tuomainen TP. Hepatitis C as a risk factor for carotid atherosclerosis - a systematic review. Clin Physiol Funct Imaging. 2015;Epub ahead of print. [PMID: 25620553 DOI: 10.1111/cpf.12229] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
7 Reyentovich A, Gidea CG, Smith D, Lonze B, Kon Z, Fargnoli A, Pavone J, Rao S, Saraon T, Lewis T, Qian Y, Jacobson I, Moazami N. Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors. Clin Transplant 2020;34. [DOI: 10.1111/ctr.13989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Iossa D, Vitrone M, Gagliardi M, Falco E, Ragone E, Zampino R, Durante-Mangoni E. Anthropometric parameters and liver histology influence lipid metabolic changes in HCV chronic hepatitis on direct-acting antiviral treatment. Ann Transl Med 2021;9:35. [PMID: 33553328 DOI: 10.21037/atm-20-669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Viganò M, Colombo M. Extrahepatic Manifestations of Hepatitis C Virus. Gastroenterol Clin North Am 2015;44:775-91. [PMID: 26600219 DOI: 10.1016/j.gtc.2015.07.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
10 Zaki MSE. The effect of Hepatitis C Virus infection on cardiovascular complications in end stage kidney disease patients on regular hemodialysis. Electron Physician 2017;9:3857-61. [PMID: 28465818 DOI: 10.19082/3857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Mazzitelli M, Torti C, Sabatino J, D'Ascoli GL, Costa C, Pisani V, Raffetti E, De Rosa S, Strazzulla A, Focà A, Liberto MC, Indolfi C; CARDIAC study group. Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients. BMC Infect Dis 2018;18:518. [PMID: 30326844 DOI: 10.1186/s12879-018-3426-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
12 Scudiero F, Valenti R, Marcucci R, Sanna GD, Gori AM, Migliorini A, Vitale R, Giusti B, De Vito E, Corda G, Paniccia R, Zirolia D, Canonico ME, Parodi G. Platelet Reactivity in Hepatitis C Virus-Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome. J Am Heart Assoc 2020;9:e016441. [PMID: 32885738 DOI: 10.1161/JAHA.120.016441] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Cacoub P, Comarmond C. New insights into HCV-related rheumatologic disorders: A review. J Adv Res 2017;8:89-97. [PMID: 28149645 DOI: 10.1016/j.jare.2016.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
14 Durazzo TC, Nguyen LC, Meyerhoff DJ. Medical Conditions Linked to Atherosclerosis Are Associated With Magnified Cortical Thinning in Individuals With Alcohol Use Disorders. Alcohol Alcohol 2020;55:382-90. [PMID: 32445335 DOI: 10.1093/alcalc/agaa034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Tassi A, Gitto S, Piras C, Cursaro C, Alicandro T, Margotti M, Rivi M, Andreone P. Cognitive, neurological and psychiatric disorders occurring in Hepatitis C Virus infection. Minerva Med 2021;112:238-45. [PMID: 33576202 DOI: 10.23736/S0026-4806.21.07388-2] [Reference Citation Analysis]
16 Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46 Suppl 5:S165-S173. [PMID: 25458776 DOI: 10.1016/j.dld.2014.10.005] [Cited by in Crossref: 163] [Cited by in F6Publishing: 145] [Article Influence: 23.3] [Reference Citation Analysis]
17 Kralj D, Virović Jukić L, Stojsavljević S, Duvnjak M, Smolić M, Čurčić IB. Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol 2016;4:66-75. [PMID: 27047774 DOI: 10.14218/JCTH.2015.00051] [Cited by in Crossref: 46] [Cited by in F6Publishing: 26] [Article Influence: 9.2] [Reference Citation Analysis]
18 Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13:297-310. [PMID: 28218263 DOI: 10.1038/nrneph.2017.16] [Cited by in Crossref: 115] [Cited by in F6Publishing: 92] [Article Influence: 28.8] [Reference Citation Analysis]
19 Ampuero J, Romero-Gómez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol. 2015;7:2214-2219. [PMID: 26380047 DOI: 10.4254/wjh.v7.i19.2214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
20 Olubamwo O, Aregbesola A, Miettola J, Kauhanen J, Tuomainen T. Hepatitis C and risk of coronary atherosclerosis – A systematic review. Public Health 2016;138:12-25. [DOI: 10.1016/j.puhe.2016.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
21 Shengir M, Elgara M, Sebastiani G. Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond. World J Gastroenterol 2021;27:1959-72. [PMID: 34007133 DOI: 10.3748/wjg.v27.i17.1959] [Reference Citation Analysis]
22 Bello-Perez M, Falco A, Novoa B, Perez L, Coll J. Hydroxycholesterol binds and enhances the anti-viral activities of zebrafish monomeric c-reactive protein isoforms. PLoS One 2019;14:e0201509. [PMID: 30653529 DOI: 10.1371/journal.pone.0201509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
23 Fu H, Zhao L, Xue J, Wu Z, Huang Y, Liu W, Gao Z. Elevated Serum Homocysteine (Hcy) Levels May Contribute to the Pathogenesis of Cerebral Infarction. J Mol Neurosci 2015;56:553-61. [DOI: 10.1007/s12031-015-0497-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
24 Bello-Perez M, Falco A, Medina-Gali R, Pereiro P, Encinar JA, Novoa B, Perez L, Coll J. Neutralization of viral infectivity by zebrafish c-reactive protein isoforms. Mol Immunol 2017;91:145-55. [PMID: 28915434 DOI: 10.1016/j.molimm.2017.09.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
25 Pagan J, Ladino M, Roth D. Treating hepatitis C virus in dialysis patients: How, when, and why? Semin Dial 2019;32:152-8. [PMID: 30475415 DOI: 10.1111/sdi.12764] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
26 Morales AL, Junga Z, Singla MB, Sjogren M, Torres D. Hepatitis C eradication with sofosbuvir leads to significant metabolic changes. World J Hepatol. 2016;8:1557-1563. [PMID: 28050236 DOI: 10.4254/wjh.v8.i35.1557] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
27 Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation. Nat Rev Nephrol 2015;11:172-82. [DOI: 10.1038/nrneph.2015.5] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
28 Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016;17. [PMID: 27231906 DOI: 10.3390/ijms17060803] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 8.6] [Reference Citation Analysis]
29 Domont F, Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver Int. 2016;36:621-627. [PMID: 26763484 DOI: 10.1111/liv.13064] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
30 Mascia C, Lichtner M, Zuccalà P, Vita S, Tieghi T, Marocco R, Savinelli S, Rossi R, Iannetta M, Campagna M, Schiavone F, Mengoni F, Russo G, Mastroianni CM, Vullo V. Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection. Clinics and Research in Hepatology and Gastroenterology 2017;41:644-55. [DOI: 10.1016/j.clinre.2017.04.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
31 Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, Hunt SL. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology. 2015;61:1798-1808. [PMID: 25627448 DOI: 10.1002/hep.27724] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 16.8] [Reference Citation Analysis]
32 Simon TG, Butt AA. Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World J Gastroenterol. 2015;21:8293-8303. [PMID: 26217081 DOI: 10.3748/wjg.v21.i27.8293] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
33 Cammarota S, Citarella A, Guida A, Conti V, Iannaccone T, Flacco ME, Bravi F, Naccarato C, Piscitelli A, Piscitelli R, Valente A, Calella G, Coppola N, Parruti G. The inpatient hospital burden of comorbidities in HCV-infected patients: A population-based study in two Italian regions with high HCV endemicity (The BaCH study). PLoS One 2019;14:e0219396. [PMID: 31291351 DOI: 10.1371/journal.pone.0219396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Perticone M, Maio R, Tassone EJ, Tripepi G, Di Cello S, Miceli S, Caroleo B, Sciacqua A, Licata A, Sesti G, Perticone F. Insulin-resistance HCV infection-related affects vascular stiffness in normotensives. Atherosclerosis. 2015;238:108-112. [PMID: 25461736 DOI: 10.1016/j.atherosclerosis.2014.11.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
35 Voulgaris T, Sevastianos VA. Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C Virus. Hepat Res Treat 2016;2016:7629318. [PMID: 26885388 DOI: 10.1155/2016/7629318] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
36 Lin SY, Lin CL, Chen WS, Lin CC, Lin CH, Hsu WH, Hsu CY, Kao CH. Association Between Alcoholic Cirrhosis and Hemorrhagic Stroke: A Nationwide Population-based Study. Alcohol Alcohol 2019;54:302-9. [PMID: 30957143 DOI: 10.1093/alcalc/agz025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Soriano V, Berenguer J. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients: . Current Opinion in HIV and AIDS 2015;10:309-15. [DOI: 10.1097/coh.0000000000000175] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
38 Esforzado N, Morales JM. Hepatitis C and kidney transplant: The eradication time of the virus has arrived. Nefrologia (Engl Ed) 2019;39:458-72. [PMID: 30905391 DOI: 10.1016/j.nefro.2019.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN)., Italian Association for the Study of the Liver (AISF)., Italian Society of Infectious and Tropical Disease (SIMIT)., Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Intern Emerg Med 2018;13:1139-66. [PMID: 30255464 DOI: 10.1007/s11739-018-1940-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Li JH, Zhu N, Min YB, Shi XZ, Duan YY, Yang YL. Ultrasonic assessment of liver stiffness and carotid artery elasticity in patients with chronic viral hepatitis. BMC Gastroenterol 2018;18:181. [PMID: 30518330 DOI: 10.1186/s12876-018-0910-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Broker M, Frager SZ, Patel NS, Lebovics E, Frishman WH. The Inflammatory Relationship Between Hepatitis C Virus With Coronary and Carotid Atherosclerosis. Cardiol Rev 2021;29:178-83. [PMID: 32618587 DOI: 10.1097/CRD.0000000000000314] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10:415-423. [PMID: 26660706 DOI: 10.1007/s12072-015-9684-3] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 12.8] [Reference Citation Analysis]
43 Van Herck J, Verbeek J, van Malenstein H, Laleman W, Cassiman D, Verslype C, van der Merwe S, Jochmans I, Sainz-Barriga M, Monbaliu D, Pirenne J, Nevens F. Liver-Related and Cardiovascular Outcome of Patients Transplanted for Nonalcoholic Fatty Liver Disease: A European Single-Center Study. Transplant Proc 2021;53:1674-81. [PMID: 34016462 DOI: 10.1016/j.transproceed.2021.02.025] [Reference Citation Analysis]
44 Mohammed AQ, Auckle R, Li HL, Xu SL, Liu L, Zhao DD, Che WL. Pegylated Interferon-α Plus Ribavirin Therapy Improves Left Ventricular Diastolic Dysfunction in Patients With Chronic Hepatitis C Attaining Sustained Virological Response. Am J Med Sci 2018;355:566-72. [PMID: 29891040 DOI: 10.1016/j.amjms.2018.02.001] [Reference Citation Analysis]
45 Osawa K, Miyoshi T, Yamauchi K, Koyama Y, Nakamura K, Sato S, Kanazawa S, Ito H. Nonalcoholic Hepatic Steatosis Is a Strong Predictor of High-Risk Coronary-Artery Plaques as Determined by Multidetector CT. PLoS One 2015;10:e0131138. [PMID: 26125952 DOI: 10.1371/journal.pone.0131138] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
46 Uslu AU, Aydin B, Balta S, Yonem O, Uncu T, Seven D. The effect of standard therapy on mean platelet volume in patients with chronic hepatitis C. Prz Gastroenterol 2016;11:200-5. [PMID: 27713783 DOI: 10.5114/pg.2016.57942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
47 Pavicic Ivelja M, Ivic I, Dolic K, Mestrovic A, Perkovic N, Jankovic S. Evaluation of cerebrovascular reactivity in chronic hepatitis C patients using transcranial color Doppler. PLoS One 2019;14:e0218206. [PMID: 31185040 DOI: 10.1371/journal.pone.0218206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Cacoub P, Comarmond C. Considering hepatitis C virus infection as a systemic disease. Semin Dial 2019;32:99-107. [PMID: 30549107 DOI: 10.1111/sdi.12758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Fabrizi F, Donato FM, Messa P.  Association between hepatitis B virus and chronic kidney disease: a systematic review and meta-analysis. Ann Hepatol 2017;16:21-47. [PMID: 28051791 DOI: 10.5604/16652681.1226813] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
50 Alexander KS, Zakai NA, Lidofsky SD, Callas PW, Judd SE, Tracy RP, Cushman M. Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The Reasons for Geographic and Racial Differences in Stroke cohort. PLoS One. 2018;13:e0194153. [PMID: 29529073 DOI: 10.1371/journal.pone.0194153] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
51 Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN)., Italian Association for the Study of the Liver (AISF)., Italian Society of Infectious and Tropical Disease (SIMIT)., Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Infection 2019;47:141-68. [PMID: 30255389 DOI: 10.1007/s15010-018-1209-2] [Reference Citation Analysis]
52 Petta S. Hepatitis C virus and cardiovascular: A review. J Adv Res 2017;8:161-8. [PMID: 28149651 DOI: 10.1016/j.jare.2016.06.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
53 Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. Am Heart J. 2018;198:4-17. [PMID: 29653647 DOI: 10.1016/j.ahj.2017.10.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
54 Melendez QM, Wooten CJ, Krishnaji ST, Knagge K, Kirchner D, Lopez D. Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9. Int J Biomed Investig 2020;3:123. [PMID: 32587953 DOI: 10.31531/2581-4745.1000123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN), the Italian Association for the Study of the Liver (AISF), the Italian Society of Infectious and Tropical Disease (SIMIT), the Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Dig Liver Dis 2018;50:1133-52. [PMID: 30266305 DOI: 10.1016/j.dld.2018.08.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
56 Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, Primorac D, Vceva A, Wu GY, Smolic M. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Front Pharmacol 2021;12:678546. [PMID: 34045969 DOI: 10.3389/fphar.2021.678546] [Reference Citation Analysis]
57 Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN)., Italian Association for the Study of the Liver (AISF)., Italian Society of Infectious and Tropical Disease (SIMIT)., Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). J Nephrol 2018;31:685-712. [PMID: 30255440 DOI: 10.1007/s40620-018-0523-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
58 Rinaldi L, Nascimbeni F, Giordano M, Masetti C, Guerrera B, Amelia A, Fascione MC, Ballestri S, Romagnoli D, Zampino R. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World J Gastroenterol. 2017;23:1458-1468. [PMID: 28293093 DOI: 10.3748/wjg.v23.i8.1458] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
59 Fabrizi F, Donato FM, Messa P. Hepatitis C and Its Metabolic Complications in Kidney Disease. Ann Hepatol. 2017;16:851-861. [PMID: 29055921 DOI: 10.5604/01.3001.0010.5275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
60 Ferro JM, Viana P, Santos P. Management of Neurologic Manifestations in Patients with Liver Disease. Curr Treat Options Neurol 2016;18:37. [PMID: 27314429 DOI: 10.1007/s11940-016-0419-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
61 Alvaro-Meca A, Berenguer J, Díaz A, Micheloud D, Aldámiz-Echevarría T, Fanciulli C, Resino S. Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era. PLoS One 2017;12:e0179493. [PMID: 28617855 DOI: 10.1371/journal.pone.0179493] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
62 Zubkin ML, Chervinko VI, Ovchinnikov YV, Kryukov EV, Kotenko ON. [Chronic HCV infection: An internist's opinion (Part 2)]. Ter Arkh 2016;88:138-48. [PMID: 28635834 DOI: 10.17116/terarkh20168811138-148] [Reference Citation Analysis]
63 Husseinzadeh H, Chiasakul T, Gimotty PA, Pukenas B, Wolf R, Kelty M, Chiang E, Fogarty PF, Cuker A. Prevalence of and risk factors for cerebral microbleeds among adult patients with haemophilia A or B. Haemophilia 2018;24:271-7. [DOI: 10.1111/hae.13398] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
64 Fabrizi F, Cerutti R, Donato FM, Messa P. HBV infection is a risk factor for chronic kidney disease: Systematic review and meta-analysis. Rev Clin Esp (Barc) 2021:S2254-8874(21)00112-0. [PMID: 34183297 DOI: 10.1016/j.rceng.2019.10.014] [Reference Citation Analysis]
65 Mathew S, Faheem M, Ibrahim SM, Iqbal W, Rauff B, Fatima K, Qadri I. Hepatitis C virus and neurological damage. World J Hepatol. 2016;8:545-556. [PMID: 27134702 DOI: 10.4254/wjh.v8.i12.545] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
66 Adinolfi LE, Rinaldi L, Nevola R. Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments? World J Gastroenterol 2018;24:4617-21. [PMID: 30416309 DOI: 10.3748/wjg.v24.i41.4617] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
67 Dächert C, Gladilin E, Binder M. Gene Expression Profiling of Different Huh7 Variants Reveals Novel Hepatitis C Virus Host Factors. Viruses 2019;12:E36. [PMID: 31905685 DOI: 10.3390/v12010036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Nagano T, Seki N, Tomita Y, Sugita T, Aida Y, Itagaki M, Sutoh S, Abe H, Tsubota A, Aizawa Y. Impact of Chronic Hepatitis C Virus Genotype 1b Infection on Triglyceride Concentration in Serum Lipoprotein Fractions. Int J Mol Sci 2015;16:20576-94. [PMID: 26334270 DOI: 10.3390/ijms160920576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
69 Xu MM, Murphy PA, Vella AT. Activated T-effector seeds: cultivating atherosclerotic plaque through alternative activation. Am J Physiol Heart Circ Physiol 2019;316:H1354-65. [PMID: 30925075 DOI: 10.1152/ajpheart.00148.2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
70 Al-rabadi L, Box T, Singhania G, Al-marji C, Agarwal A, Hall I, Gordon CE, Tran H. Rationale for treatment of hepatitis C virus infection in end-stage renal disease patients who are not kidney transplant candidates: HCV treatment in ESRD patients. Hemodialysis International 2018;22:S45-52. [DOI: 10.1111/hdi.12656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
71 LaHue SC, Torres D, Rosendale N, Singh V. Stroke Characteristics, Risk Factors, and Outcomes in Transgender Adults: A Case Series. Neurologist 2019;24:66-70. [PMID: 30817494 DOI: 10.1097/NRL.0000000000000226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, Saadoun D, Desbois AC, Sebastiani M, Casato M. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15:1145-1160. [PMID: 27640316 DOI: 10.1016/j.autrev.2016.09.006] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 12.6] [Reference Citation Analysis]
73 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016;22:9674-9693. [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 57] [Article Influence: 16.3] [Reference Citation Analysis]
74 Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, Mallolas J, Crespo M, Téllez MJ, Quereda C, Sanz J, Barros C, Tural C, Santos I, Pulido F, Guardiola JM, Rubio R, Ortega E, Montes ML, Jusdado JJ, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group. Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2017;66:344-56. [PMID: 28109003 DOI: 10.1002/hep.29071] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
75 Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3:3-14. [PMID: 26862398 DOI: 10.1177/2049936115585942] [Cited by in Crossref: 62] [Cited by in F6Publishing: 78] [Article Influence: 12.4] [Reference Citation Analysis]
76 Huang QT, Hang LL, Zhong M, Gao YF, Luo ML, Yu YH. Maternal HCV infection is associated with intrauterine fetal growth disturbance: A meta-analysis of observational studies. Medicine (Baltimore) 2016;95:e4777. [PMID: 27583932 DOI: 10.1097/MD.0000000000004777] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
77 Marra F, Höner Zu Siederdissen C, Khoo S, Back D, Schlag M, Ouwerkerk-Mahadevan S, Bicer C, Lonjon-Domanec I, Jessner W, Beumont-Mauviel M, Kalmeijer R, Cornberg M. Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. Br J Clin Pharmacol 2018;84:961-71. [PMID: 29345798 DOI: 10.1111/bcp.13519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
78 Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67:2025-2034. [PMID: 29703790 DOI: 10.1136/gutjnl-2018-316234] [Cited by in Crossref: 70] [Cited by in F6Publishing: 54] [Article Influence: 23.3] [Reference Citation Analysis]
79 Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, Antonelli A, Desbois AC, Comarmond C, Gragnani L, Casato M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P; ISG-EHCV. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017;16:523-541. [PMID: 28286108 DOI: 10.1016/j.autrev.2017.03.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 13.0] [Reference Citation Analysis]
80 Ferro JM, Oliveira S. Neurologic manifestations of gastrointestinal and liver diseases. Curr Neurol Neurosci Rep. 2014;14:487. [PMID: 25171900 DOI: 10.1007/s11910-014-0487-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
81 Gentile I, Zappulo E, Buonomo AR, Maraolo AE, Borgia G. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs 2015;24:1111-21. [PMID: 26156630 DOI: 10.1517/13543784.2015.1059820] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
82 Gitto S, Cicero AF, Loggi E, Giovannini M, Conti F, Grandini E, Guarneri V, Scuteri A, Vitale G, Cursaro C, Borghi C, Andreone P. Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment. Annals of Hepatology 2018;17:64-75. [DOI: 10.5604/01.3001.0010.7536] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
83 Zhang T, Jiang Y, Zhang S, Tie T, Cheng Y, Su X, Man Z, Hou J, Sun L, Tian M, Zhang Y, Li J, Ma Y. The association between homocysteine and ischemic stroke subtypes in Chinese: A meta-analysis. Medicine (Baltimore) 2020;99:e19467. [PMID: 32195946 DOI: 10.1097/MD.0000000000019467] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
84 Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, Zampino R, Rinaldi L, Sellitto A, Giordano M, Marrone A. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol. 2015;21:2269-2280. [PMID: 25741133 DOI: 10.3748/wjg.v21.i8.2269] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 53] [Article Influence: 13.2] [Reference Citation Analysis]
85 Romagnoli D, Marrazzo A, Ballestri S, Lonardo A, Bertolotti M. Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma. J Clin Virol 2015;69:74-7. [PMID: 26209383 DOI: 10.1016/j.jcv.2015.05.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
86 Fabrizi F, Messa P. Managing hepatitis C therapy failures and chronic kidney disease. Expert Rev Clin Pharmacol 2018;11:1135-42. [PMID: 30309263 DOI: 10.1080/17512433.2018.1534202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Sasso FC, Pafundi PC, Caturano A, Galiero R, Vetrano E, Nevola R, Petta S, Fracanzani AL, Coppola C, Di Marco V, Solano A, Lombardi R, Giordano M, Craxi A, Perrella A, Sardu C, Marfella R, Salvatore T, Adinolfi LE, Rinaldi L. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. Nutrition, Metabolism and Cardiovascular Diseases 2021;31:2345-53. [DOI: 10.1016/j.numecd.2021.04.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Int J Mol Sci. 2016;17:355. [PMID: 27005620 DOI: 10.3390/ijms17030355] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
89 Huang H, Kang R, Zhao Z. Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis. PLoS One. 2014;9:e106376. [PMID: 25184517 DOI: 10.1371/journal.pone.0106376] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
90 Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, Chung RT, Curry MP, Hanifi JM, Gabardi S. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. PLoS One. 2016;11:e0158431. [PMID: 27415632 DOI: 10.1371/journal.pone.0158431] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 12.6] [Reference Citation Analysis]
91 Bedimo R, Abodunde O. Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients. Curr HIV/AIDS Rep. 2016;13:328-339. [PMID: 27595755 DOI: 10.1007/s11904-016-0333-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
92 Su X, Zhao X, Deng JL, Li SN, Du X, Dong JZ, Ma CS. Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis. J Viral Hepat 2021;28:664-71. [PMID: 33452699 DOI: 10.1111/jvh.13469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Fabrizi F, Donato FM, Messa P. Association Between Hepatitis C Virus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Ann Hepatol 2018;17:364-91. [PMID: 29735788 DOI: 10.5604/01.3001.0011.7382] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 9.7] [Reference Citation Analysis]
94 Romano C, Cuomo G, Ferrara R, Del Mastro A, Esposito S, Sellitto A, Adinolfi LE. Uncommon immune-mediated extrahepatic manifestations of HCV infection. Expert Rev Clin Immunol. 2018;14:1089-1099. [PMID: 30338718 DOI: 10.1080/1744666x.2018.1538790] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
95 Mohanty A, Salameh S, Butt AA. Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection. Curr HIV/AIDS Rep 2019;16:389-94. [PMID: 31482299 DOI: 10.1007/s11904-019-00466-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
96 Fabrizi F, Cerutti R, Dixit V, Messa P. The impact of antiviral therapy for HCV on kidney disease: a systematic review and meta-analysis. Nefrologia (Engl Ed) 2020;40:299-310. [PMID: 31813592 DOI: 10.1016/j.nefro.2019.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Wang C, Cheng P, Kao J. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther 2020;51:216-30. [DOI: 10.1111/apt.15575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]